Biotech entity
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Department of Health and Social Care, the most common co-covered peer. NICE appears in 1 tracked Biotech story from March 6, 2026.
Last mentioned: Mar 6, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Department of Health and Social Care, the most common co-covered peer. NICE appears in 1 tracked Biotech story from March 6, 2026. The tracked stories average 11 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering NICE. Shared-story counts are live from our verified record — not editorial picks.
Scheduled Re-evaluation
NICE appraisal committee is set to meet for a second round of evidence review.
Public Campaign Launch
Bereaved family launches a national campaign imploring the NHS to reconsider the approval.
NICE Initial Review
NICE issues a preliminary recommendation against the drug due to cost-effectiveness concerns.
FDA Approval
The treatment receives accelerated approval in the United States for aggressive cancer types.
A bereaved family's public campaign has reignited a national debate over the NHS's drug appraisal process for aggressive cancers. The movement highlights the growing tension between fiscal cost-effectiveness and the urgent need for life-extending therapies already available in other markets.
Source: surreycomet.co.uk · burytimes.co.uk
NICE is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
